Vasomotor symptoms, otherwise known as VMS due to menopause, are characterized as hot flashes and/or night sweats that can impact many aspects of your life such as sleep, ability to focus, and ...
Neurokinin is crucial in the pathophysiology of vasomotor symptoms linked to menopause, offering a target for novel treatments. Fezolinetant, a nonhormonal agent, antagonizes neurokinin-3 receptors to ...
TOKYO, March 3, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced dosing of the first patient in the STARLIGHT™ 2 Phase 3 pivotal ...
Study evaluated 24-week efficacy and safety of Astellas' fezolinetant in women considered unsuitable for hormone therapy TOKYO, June 27, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President ...
While no one understands the exact mechanism behind VMS, their trigger is mostly due to the decline of estrogen at the time of menopause, explains Lisa Brent, ND, founder and medical director of Be ...
Late-breaking data from pivotal Phase III studies OASIS 1 and 2 to be presented at 2024 ACOG Annual Meeting: Pivotal OASIS 1 and 2 Phase III studies of investigational compound elinzanetant achieved a ...
The MarketWatch News Department was not involved in the creation of this content. -- Detailed results from the Phase III OASIS 3 study evaluating the efficacy and long-term safety of investigational ...
(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) said that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion relating to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback